Analyst Price Targets — MNMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 13, 2025 9:56 am | Ami Fadia | Needham | $28.00 | $11.81 | TheFly | Mind Medicine initiated with a Buy at Needham |
| March 7, 2025 12:35 pm | — | Robert W. Baird | $16.00 | $6.83 | TheFly | Mind Medicine price target lowered to $16 from $27 at Baird |
| September 16, 2024 8:07 am | Sumart Kulkami | Canaccord Genuity | $14.00 | $6.45 | StreetInsider | MindMed (MNMD) PT Lowered to $14 at Canaccord Genuity |
| June 5, 2024 6:14 am | Brian Abrahams | RBC Capital | $22.00 | $8.25 | StreetInsider | RBC Capital Reiterates Outperform Rating on MindMed (MNMD) |
| May 13, 2024 7:36 am | Francois Brisebois | Oppenheimer | $20.00 | $8.61 | StreetInsider | MindMed (MNMD) PT Lowered to $20 at Oppenheimer |
| November 16, 2022 6:10 am | — | RBC Capital | $5.00 | $2.86 | Benzinga | RBC Capital Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $5 |
No recent news available for MNMD.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNMD.
U.S. House Trading
No House trades found for MNMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.